Levodropropizine

Levodropropizine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R05DB27 (WHO) ;
Pharmacokinetic data
Protein binding	11-14%
Excretion	83% via urine within 96 h
Identifiers
	IUPAC name (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol;
CAS Number	99291-25-5 ;
PubChem CID	65859;
DrugBank	DB12472 ;
ChemSpider	59270 ;
UNII	3O31P6T4G3;
KEGG	D08119 ;
ChEBI	CHEBI:82722 ;
CompTox Dashboard (EPA)	DTXSID8023210 ;
ECHA InfoCard	100.167.719
Chemical and physical data
Formula	C13H20N2O2
Molar mass	236.315 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@@H](CN2CCN(c1ccccc1)CC2)CO;
	InChI InChI=1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1 ; Key:PTVWPYVOOKLBCG-ZDUSSCGKSA-N ;
	(what is this?) (verify)

Levodropropizine is a cough suppressant. It is the levo isomer of dropropizine. It acts as a peripheral antitussive, with no action in the central nervous system.^[1] It does not cause side effects such as constipation or respiratory depression which can be produced by opioid antitussives such as codeine and its derivatives.

References